Physicians' Academy for Cardiovascular Education

NOAC reduces major CV complications in patients with myocardial injury after noncardiac surgery

Dabigatran in myocardial injury after noncardiac surgery

Presented at ACC.18 by dr. PJ Devereaux (McMaster University in Hamilton, ON, Canada)

News - Mar. 10, 2018

Main results

Conclusion

This study shows that patients who have MINS are at substantial risk of major vascular complications. Without routine post-operative troponin measurement, most cases of MINS will go unnoticed. Among patients with MINS, dabigatran 100 mg BID resulted in lower risk of major vascular complications as compared with placebo.

Almost half of patients discontinued study drug. The most common reason for drug discontinuation was patient request; however, 14 percent of these patients had a major complication (e.g., heart attack, stroke, bleeding). Devereaux notes in a press release that analyses that counted patients up to seven days after they discontinued the study drug showed even larger treatment effects, with 46 percent reductions in major CV complications with dabigatran and no excess of life-threatening, major or critical organ bleeding.

Disclosures

Our coverage of ACC.18 is based on the information provided during the congress.

Listen to PJ Devereaux discuss the results of the MANAGE trial

Share this page with your colleagues and friends: